Commentary
Podcast
Author(s):
Lucio Gordan, MD, president and managing physician of Florida Cancer Specialists & Research Institute, discusses recently updated clinical guidelines from the National Comprehensive Cancer Network (NCCN) in multiple myeloma, which specifically discuss disease staging and risk stratification and advise clinicians on how to address 1q abnormalities.
In this edition of Managed Care Cast, Executive Editor Mary Caffrey speaks with Lucio Gordan, MD, president and managing physician of Florida Cancer Specialists & Research Institute. Gordan discusses recently updated clinical guidelines from the National Comprehensive Cancer Network (NCCN) in multiple myeloma, which specifically discuss disease staging and risk stratification and advise clinicians on how to address 1q abnormalities.
Review the NCCN guideline update discussed in this podcast.
The guidelines follow the Second revision of the International Staging System (R2-ISS), which appeared in the December 2022 issue of the Journal of Clinical Oncology, the official publication of the American Society of Clinical Oncology.1
Listen above or on one of these podcast services:
Reference